How much does Jakavi (Ruxolitinib Phosphate Tablets) Cost& price without insurance in China?
Jakavi® is the commercial brand name of Ruxolitinib Phosphate Tablets, an orally active selective JAK1/JAK2 inhibitor developed by Novartis. It blocks abnormal JAK-STAT signaling pathway to relieve splenomegaly and disease-related symptoms caused by myeloproliferative neoplasms.
Main Indications
Treatment of intermediate or high-risk myelofibrosis including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis;
Treatment of polycythemia vera resistant or intolerant to hydroxyurea.
Common Side Effects
Common mild adverse reactions: Anemia, thrombocytopenia, headache, dizziness and fatigue.
Laboratory abnormalities: Decreased peripheral blood cell counts and transient liver function fluctuation.
Severe but manageable risks: Severe myelosuppression, opportunistic infection and hypersensitivity reactions.
Approval Status in China
Jakavi® (Ruxolitinib Phosphate Tablets, 5mg) was officially approved for marketing in China in 2017. It is currently a prescription drug included in China’s Category B medical insurance.
Buy Jakavi (Ruxolitinib Phosphate Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
